VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Cognitive impairment from mild to moderate degree  │ Cognitive impairment from mild to moderate degree  │     100 │
│ defined by a Clinical Deterioration Rating (CDR)   │ defined by a Clinical Deterioration Rating (CDR)   │         │
│ score range between 0.5 and 2.0                    │ score range between 0.5 and 2.0                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence on brain MRI of white matter              │ Evidence on brain MRI of white matter              │     100 │
│ hyperintensities (leukoaraiosis of moderate or     │ hyperintensities (leukoaraiosis of moderate or     │         │
│ severe degree according to the modified Fazekas    │ severe degree according to the modified Fazekas    │         │
│ visual scale and/or presence of lacunar infarcts)  │ visual scale and/or presence of lacunar infarcts)  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Consent to participation in the study              │ Consent to participation in the study              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of objectionable cognitive impairment or   │ Absence of objectionable cognitive impairment or   │     100 │
│ presence of dementia of severe degree defined by   │ presence of dementia of severe degree defined by   │         │
│ CDR score \> 2.0                                   │ CDR score > 2.0                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unavailability of brain MRI (in case of absolute   │ Unavailability of brain MRI (in case of absolute   │     100 │
│ contraindications, the use of cranial CT is        │ contraindications, the use of cranial CT is        │         │
│ allowed)                                           │ allowed)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Expected poor compliance with the study protocol   │ Expected poor compliance with the study protocol   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Past diagnosis of major depression, schizophrenia, │ Past diagnosis of major depression, schizophrenia, │     100 │
│ major anxiety syndrome, or manic- depressive       │ major anxiety syndrome, or manic- depressive       │         │
│ illness                                            │ illness                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of degenerative cognitive impairment     │ Diagnosis of degenerative cognitive impairment     │     100 │
│ based on clinical and/or neuroradiological         │ based on clinical and/or neuroradiological         │         │
│ findings (i.e., patients with prevailing memory    │ findings (i.e., patients with prevailing memory    │         │
│ impairment, or with medial temporal atrophy on     │ impairment, or with medial temporal atrophy on     │         │
│ brain MRI in absence of evident vascular           │ brain MRI in absence of evident vascular           │         │
│ abnormalities; i.e., Alzheimer disease as defined  │ abnormalities; i.e., Alzheimer disease as defined  │         │
│ using the National Institute of Neurological and   │ using the National Institute of Neurological and   │         │
│ Communicative Disorders and Stroke/Alzheimer's     │ Communicative Disorders and Stroke/Alzheimer's     │         │
│ Disease and Related Disorders Association          │ Disease and Related Disorders Association          │         │
│ criteria, Parkinson disease, Huntington disease,   │ criteria, Parkinson disease, Huntington disease,   │         │
│ frontotemporal dementia)                           │ frontotemporal dementia)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of cognitive impairment from other       │ Diagnosis of cognitive impairment from other       │     100 │
│ causes (i.e., vitamine B12 and folic acid          │ causes (i.e., vitamine B12 and folic acid          │         │
│ deficiency, thyroid disorders, metabolic diseases, │ deficiency, thyroid disorders, metabolic diseases, │         │
│ head trauma, tumor or infections of the central    │ head trauma, tumor or infections of the central    │         │
│ nervous system, normal pressure hydrocephalus)     │ nervous system, normal pressure hydrocephalus)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical conditions expected to progress, recur, or │ Medical conditions expected to progress, recur, or │     100 │
│ change to such a degree to interfere with the      │ change to such a degree to interfere with the      │         │
│ assessment of the clinical and mental status       │ assessment of the clinical and mental status       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically relevant cardiac or pulmonary           │ Clinically relevant cardiac or pulmonary           │     100 │
│ insufficiency                                      │ insufficiency                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Relevant electrocardiograph abnormalities;         │ Relevant electrocardiograph abnormalities;         │     100 │
│ bradycardia (50 bpm) or tachycardia (120 bpm)      │ bradycardia (50 bpm) or tachycardia (120 bpm)      │         │
│ under resting conditions                           │ under resting conditions                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Myocardial infarction within the past 6 months     │ Myocardial infarction within the past 6 months     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stroke still requiring neurological rehabilitation │ Stroke still requiring neurological rehabilitation │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe/untreated blood pressure (systolic 180 mm   │ Severe/untreated blood pressure (systolic 180 mm   │     100 │
│ Hg, diastolic 95 mm Hg)                            │ Hg, diastolic 95 mm Hg)                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically relevant liver function impairment      │ Clinically relevant liver function impairment      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Insulin-dependent diabetes mellitus                │ Insulin-dependent diabetes mellitus                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Idiopathic epilepsy and anti-epileptic treatment   │ Idiopathic epilepsy and anti-epileptic treatment   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe gastrointestinal disease                    │ Severe gastrointestinal disease                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cancer                                             │ Cancer                                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known intolerance to study drugs                   │ Known intolerance to study drugs                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Coexistent serious illnesses that would imply a    │ Coexistent serious illnesses that would imply a    │     100 │
│ drop-out before the end of the trial               │ drop-out before the end of the trial               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe anemia (Hb \<10 mg/dL)                      │ Severe anemia (Hb <10 mg/dL)                       │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                         │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════╪═════════╡
│ Must have minimum age of 65 Years │ Consent to participation in the study │      34 │
╘═══════════════════════════════════╧═══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.16666666666667
OverAll Ratio: 98.08333333333334
